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Abstract
Habitual intake of black tea has been associated with relatively lower serum cholesterol 
concentrations in observational studies. However, clinical trial results evaluating the effects of 
black tea on serum cholesterol have been inconsistent. Several factors could explain these mixed 
results, in particular, uncontrolled confounding caused by lifestyle factors, e.g. diet. This diet-
controlled clinical trial estimates the effect of black tea flavonoid consumption on cholesterol 
concentrations in 57 borderline hypercholesterolemic individuals (total cholesterol concentrations 
between 190 and 260 mg/dl (4.9 and 6.7 mmol/L)). A double blind, randomized crossover trial 
was conducted in Minneapolis, MN from April 2002 through April 2004, wherein key conditions 
were tightly controlled to minimize possible confounding. Participants consumed a controlled 
low-flavonoid diet plus 5 cups per day of black tea or tea-like placebo over two 4-week treatment 
periods. The flavonoid-free caffeinated placebo matched the tea in color and taste. Differences in 
cholesterol concentrations at the end of each treatment period were evaluated via linear mixed 
models. Differences (95% CI) in mg/dl among those treated with tea versus placebo were 3.43 
(−7.08, 13.94) for total cholesterol, −1.02 (−11.34, 9.30) for low-density lipoprotein cholesterol 
(LDL-C), 0.58 (−2.98, 4.14) for high-density lipoprotein cholesterol (HDL-C), 15.22 (−40.91, 
71.35) for triglycerides, and −0.39 (−11.16, 10.38) for LDL plus HDL cholesterol fraction. The 
LCL-C/HDL-C ratio decreased by −0.1 units (95% CI −0.41, 0.21). No results were statistically or 
clinically significant. Thus, the intake of 5 cups of black tea per day did not significantly alter the 
lipid profile of borderline hypercholesterolemic subjects.
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INTRODUCTION
Tea brewed from Camellia sinensis is the most commonly consumed beverage in the world 
after water.1,2 It is rich in polyphenolic flavonoids that possess antioxidant, anti-mutagenic, 
anti-inflammatory, and antiallergenic properties.3 These flavonoids may also be 
hypocholesterolemic,3–5 as shown in cell culture,6–8 animal,4,6,9–21 and observational22–32 
studies of black tea, the most commonly consumed tea in the United States. Clinical trial 
results, however, have been inconsistent.33–39 Some randomized trials have found 
significant hypocholesterolemic associations between black tea consumption and lipid 
profiles,33,36,39 while others have reported no effect on lipid profiles.34,35,37,38 A review on 
the subject found limited evidence that tea has favorable effects on cardiovascular disease 
risk factors, including hypercholesterolemia.40 It urged cautious interpretation of the results 
due to the small number of potentially biased trials, and emphasized the need for further 
high quality trials with longer-term follow-up.
Several factors may contribute to the mixed results of previous black tea and cholesterol 
trials, such as varying study duration, strength and brewing method of tea, average habitual 
tea consumption, and differences in participants’ dietary habits. Prior studies, with the 
exception of one clinical trial, have not rigorously controlled all of these factors.36 The trial 
presented herein addresses prior deficits in the black tea and serum lipid literature by 
examining the effect of black tea beverage intake (5 cups/day, 700 mg tea solids/cup) on 
serum lipid concentrations using a standardized tea treatment and appropriate and consistent 
placebo in the presence of a completely controlled diet.
METHODS
Participants
Between April 2002 and April 2004, 1500 individuals were recruited via TV, radio, and 
print advertisements in Minneapolis and St. Paul, MN. They were screened via telephone for 
eligibility prior to secondary screening at the University of Minnesota General Clinical 
Research Center (GCRC, currently the Clinical and Translational Science Institute), where a 
screening blood draw occurred. Basic eligibility criteria included age 45–65 years, 
borderline hypercholesterolemia (total cholesterol concentrations 190–260 mg/dl or 4.9–6.7 
mmol/L), 35–65 mg/dl (0.9–1.6 mmol/L) of high-density lipoprotein cholesterol (HDL-C), 
and triglyceride (TG) concentrations <600 mg/dl (6.8 mmol/L). A slightly wider range than 
standard borderline hypercholesterolemia was utilized.41 See on-line supplemental materials 
for additional inclusion/exclusion criteria.
Of the 1500 people initially screened, 400 (26.7%) were eligible and provided consent for 
secondary screening at the GCRC. Of these 400, 57 (14.3%) volunteers met all entry 
criteria, consented to participate, and were enrolled. Informed consent was obtained via a 
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structured interview with the study coordinator prior to both screening and enrollment. The 
University of Minnesota, Twin Cities Institutional Review Board approved this study. The 
trial is registered at ClinicalTrials.gov (NCT01882283).
Study Design
At the end of a one-week run-in period, 57 participants were block-randomized by sex using 
a computer-generated list to initial consumption of either 5 cups per day of black tea or 
placebo (tea-like) beverage. Block randomization was used to equally distribute potential 
differences within sexes, e.g. metabolism, across randomization arms. Participants switched 
treatment assignments at the beginning of the second treatment period. Serum lipid values 
were measured at baseline, and the beginning and end of each treatment period. Research 
team members, participants and analysts remained blinded until the final analysis was 
completed. Only the study statistician had access to randomization codes.
Intervention
The intervention consisted of 5 cups per day of black tea or a tea-like placebo for 4 weeks, 
plus a provided, low-flavonoid diet. The trial included two 41-day treatment periods and a 3-
week washout period, which occurred between the treatment periods. Each treatment period 
was comprised of 13 days of run-in time and 28 days of tea or placebo treatment. All 
participants consumed tea-like placebo during run-in periods. The isocaloric study diet was 
consumed throughout run-in and treatment periods, which allowed for a flavonoid washout 
from the self-selected diet consumed during the washout period. An overview of the entire 
study period and biological sample collection are described in Figure 1.
Black tea was selected for this intervention because it is the most commonly consumed form 
of tea in U.S. The selection of five cups of tea per day was based on 1) its therapeutic 
potential, and 2), that if therapeutic, this volume could be reasonably incorporated into a 
patient’s daily routine. Significant effects on plasma cholesterol concentration, platelet 
aggregation, brachial artery reactivity, and oxidative damage, given response times, could 
occur within a one-month period of tea intake, hence the 28-day treatment period.3,42–45 The 
washout period duration allowed for re-equilibration of parent catechin and catechin 
metabolite concentrations to self-selected diet concentrations following tea intake.46–50
Tea Treatment and Placebo
Black tea and tea-like preparations arrived in identical individual serving packets from the 
Lipton Tea Company (currently Unilever-Best Foods NA), and were coded with randomly 
generated numbers that linked their content to the treatment assignment in a blinded fashion. 
They were pre-brewed, and matched in terms of color and taste, caffeine, aspartame, malic 
acid and fruit flavor content (On-line Supplemental Table 1). The flavonoid composition of 
the black tea treatment is described in the On-line Supplemental Table 2.
Participants were given specific treatment preparation instructions, and the tea/placebo was 
prepared for drinking and consumed off-site. If desired, the addition of sweetener to the 
beverage was allowed, but not milk. Participants were encouraged to consume the treatment 
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at equal intervals throughout the day, but no mandatory times were specified. No specific 
limit was set on the amount of water that could be added to the preparation or the cup size.
Controlled Low-Flavonoid Diet
Participants were to consume the entire controlled low-flavonoid diet and daily water-
soluble vitamin supplements (100% RDA), which were provided throughout each treatment 
period. Due to the low naturally occurring vitamin content of the controlled diet, vitamin 
supplementation was given for ethical reasons. With the exception of calorie-free and 
decaffeinated soft drinks, consumption of non-study provided foods was not permitted. All 
pain relievers (besides acetaminophen) were restricted.
The Nutrition Data System for Research Software for commercial entrees (Version 4.04_32, 
2001, Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN) was used 
to determine the food composition of the study diet entrees, and to identify entree 
components that may contain flavonoids. Entrees with a possible significant flavonoid 
content were not used. Prior to the study, the nutritional composition of the entire study diet 
was calculated using Nutritionist V nutrient analysis software (Version 2.3, 2000, First Data 
Bank, San Bruno, CA). The macronutrient composition of the study diet was 15% protein, 
51% carbohydrate, and 34% fat. The ratio of saturated, monounsaturated, and 
polyunsaturated fatty acids was 1:1:0.6 to meet usual intake values as reported in the 
National Health and Nutrition Examination Survey III.53
Nutritional composition was later re-analyzed using the Grand Forks Research Analysis of 
Nutrient Data software (Release 24, 2011, Grand Forks Human Nutrition Research Center, 
Agricultural Research Service, U.S. Department of Agriculture, Grand Forks, ND), to 
determine the additional macronutrient values reported here.51,52 The diet contained 12.8 g 
saturated fat, 14.1 g monounsaturated fat, 7.8 g polyunsaturated fat and 6.3 g fiber per 1000 
kcals. The diet, which contained no fruits and very small amounts of vegetables, was 
analyzed for multiple flavonoids. No flavonoids were detected. A detailed description of this 
analysis is found in the on-line supplemental materials.
Participants were assigned energy intake estimates congruent with weight maintenance. The 
study diet was comprised of a 5-day menu rotation, and calculated at five different energy 
levels: 2000, 2500, 3000, 3500, and 4000 kcal. Energy intake estimates were calculated 
using Harris Benedict Equation, multiplied by an estimated activity factor.54–56 The activity 
factors, ranging from 1.4-sedentary to 2.0-very active, were estimated using subjects’ self-
reported physical activity levels.56 A unit-muffin of 100 kcal, which matched the diet’s 
exact macronutrient composition, was used to ensure weight maintenance. The results of 
daily weighs informed the need for energy intake modification.
Measures
Participants visited the GCRC Monday through Friday throughout the study for daily 
weighs, and to collect meals. Once per week, GCRC nurses measured each subject’s weight, 
blood pressure, and pulse, and completed blood draws and urine collections. During these 
nurse evaluations, participants were interviewed to evaluate pharmaceutical usage, dietary 
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intake, and motivation to maintain study requirements. The number of tea packets used was 
also counted to evaluate treatment compliance.
All compliance to treatment, provided diet, non-study beverage restriction, non-study food 
consumption, multivitamin intake, and pharmaceutical use was self-reported on daily 
compliance records, either at GCRC (weekdays) or at home (weekend days). Participants 
were asked to describe the type of deviation and its magnitude, e.g. mg of restricted 
medication. No biologic analyses were conducted to verify compliance.
Biological Samples—Morning measurements from Day 1 of the first tea/placebo 
treatment period established baseline data for weight, blood pressure, and serum lipids. 
Thereafter, fasting serum samples were collected on days 7, 14, 21 and 28 of each treatment 
period. Blood was collected in 2.5 ml Serum Separation Tubes (Becton Dickinson, Franklin 
Lanes, NJ), and the resulting serum sample was analyzed for TC, HDL-C, and TG at the 
University of Minnesota Medical Center, Fairview Collaborative Studies Clinical 
Laboratory (Minneapolis, MN), using the COBAS FARA instrument (Roche Analytical 
Instruments, Inc. Nutley, NJ). Serum total cholesterol, HDL-C and TG were measured 
enzymatically.57 HDL-C was determined after precipitation of LDL-containing lipoproteins 
with dextran sulfate/magnesium.58 LDL-C was calculated in participants with TG 
concentrations <400 mg/dl (<4.5 mmol/L) by the Friedewald equation.59
Analyses
At an α level of 0.05, the trial had 95% power to detect differences of 6.69 mg/dl of TC (0.2 
mmol/L), 4.57 mg/dl of LDL-C (0.1 mmol/L), 1.37 mg/dl of HDL-C (0.04 mmol/L), and 
22.79 mg/dl of TG (0.3 mmol/L) between treatment groups. These values are similar to, but 
more conservative than, what was found in Davies et al trial.36 Equivalence of mean 
baseline characteristic values was analyzed using one-way ANOVA to ensure that important 
covariates were equally distributed across randomization groups. A paired t-test was used to 
evaluate treatment carry-over effects between baseline and Day 1 lipid concentrations.
Differences in lipid concentrations across treatment groups were calculated using the Day 28 
serum measurement taken at the end of each treatment period. The effect of tea consumption 
on each lipid concentration was analyzed as a repeated measures regression using the PROC 
MIXED procedure in SAS (Version 8.2, released 2001, SAS Institute, Inc., Cary, NC). 
Analyses were adjusted for treatment period via the inclusion of a period covariate. 
Treatment-period interactions were also tested. All data analyses followed intention-to-treat 
(ITT) principles. Results were considered statistically significant at an alpha level of 0.05.
RESULTS AND DISCUSSION
Participants and Compliance
The study sample consisted of 32 men and 25 women, who had a mean age of 52.4 years 
(range 45–65). Baseline characteristics of participants by treatment-order assignment are 
summarized in Table 1. Thirty participants were randomized to consume black tea treatment 
and 27 were randomized to placebo in the first treatment period. No statistically significant 
difference was observed in the baseline characteristics across treatment groups, except for 
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HDL-C concentration, which was slightly lower among participants starting the tea 
treatment first (p=0.04).
Post-randomization, two participants left the study for reasons unrelated to treatment during 
the first treatment period. One participant moved out of state, and another demonstrated 
willful non-participation in the study. No significant changes in body weight occurred 
during the study period. No compliance violations were found regarding drug intake, with 
the exception of one subject who took aspirin on two occasions. Compliance rates on all 
other indicators were above 96% (On-line Supplemental Table 3).
Blood Lipids
No period effects or treatment-period interactions were detected. At the end of the study 
period, mean differences in absolute values were +1.64% for total cholesterol (mean 
difference 3.43; 95%CI: −7.08, 13.94; p-value=0.2), −0.77% for low-density lipoprotein 
cholesterol (LDL-C) (mean difference −1.02; 95% CI: −11.34, 9.30; p-value=0.7), +1.40% 
for high-density lipoprotein cholesterol (HDL-C) (mean difference 0.58; 95%CI: −2.98, 
4.14; p-value=0.3), +7.81% for triglycerides (mean difference 15.22; 95%CI: −40.91, 71.35; 
p-value=0.1), −0.22% for LDL plus HDL cholesterol fraction (mean difference −0.39 ; 95% 
CI: −11.16, 10.38; p-value=0.9) in those treated with tea versus placebo. There was a 
−3.08% difference in mean LDL-C/HDL-C ratio values across treatment periods (mean 
difference −0.1; 95%CI −0.41, 0.21; p-value=0.2). Mean absolute values (± standard error) 
across treatment groups, mean differences, and p-values for all lipid categories are shown in 
Table 2. The trial results indicated that consumption of 5 cups of tea per day for four weeks 
did not significantly change TC, LDL-C plus HDL-C, LDL-C, HDL-C, or TG 
concentrations.
The current study is the only clinical trial to date to isolate the effect of consuming the 
polyphenolic flavonoids found in black tea beverage on cholesterol concentrations, while 
strictly controlling dietary intake. This trial excluded current smokers, included stringent 
inclusion criteria, controlled caffeinated beverage and pharmaceutical use, and used 
participants as their own controls to maximize its internal validity. Critically, this study 
compared black tea beverage to an appropriate placebo (matched to tea treatment with the 
exception of flavonoids) according to a pre-specified protocol.
The results of this study contradict the majority of observational research and animal trials, 
and three clinical trials, one of which was also diet-controlled.9,10,17,19–21,23–27,33,36,39,60 
The strong cholesterol lowering effects of black tea found in animal and cell culture studies 
may be due to the high doses (mg/kg) used in those studies versus most human research. 
Seven observational studies (six cross-sectional and one case-control) have reported that 
black tea consumption is correlated with lower total cholesterol in humans.23–27,31,32 
However, other observational studies (three cross-sectional and one prospective) found no 
association between tea drinking and total cholesterol.22,28–30 Tea consumption may be a 
surrogate marker for lifestyle factors that could serve as confounders, e.g. exercise habits, 
smoking patterns, lower coffee consumption, or dietary differences. Incomplete adjustment 
for these factors, differences of consumed tea quantity, and/or differences in types (e.g. 
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blended, decaffeinated, instant) and preparation (e.g. brewing time, amount used, brewing 
temperature) of tea consumed may explain the inconsistent results of observational studies.
Results of the current study are in agreement with four other clinical trials.34,35,37,38 While 
the direction of the results was similar, these trials differed in methodology from the current 
trial (treatment type, duration, target population). Some had methodological weaknesses that 
may have had an important effect on their results, e.g. allowing participants to consume 
variable amounts of tea and coffee, small sample size.35,37 Two other randomized clinical 
trials, which also did not control background diet, found that black tea had 
hypocholesterolemic effects.33,39 These two trials differed methodologically from the 
present study in multiple ways. Neither study compared within-participant serum lipid 
values. Bahorun et al. compared black tea intake to a hot water placebo in healthy adults. 
The study experienced differential loss to follow-up, totaling approximately 12% of their 
study population, and no ITT analysis was reported. Fujita et al. compared the effects of 
black tea extract capsules (333 mg x 3/day) to a placebo for a three-month period, and also 
measured serum lipids at 1 month post-intervention. These results indicated an 8.5% 
decrease in TC, a 8.4% decrease in TG and 11.8% decrease in LDL-C after 3 months, which 
were all statistically significant at p-value of 0.01. The difference in results from Fujita et al. 
and this study may be driven primarily by treatment type (extract capsules from fermented 
fenhai broad-leaf tea vs. powdered tea drink), due to the highly concentrated nature of the 
extract capsules. Also, analyses compared treatment groups to changes over time within 
each group, and did not present the results of comparisons between groups.
The current trial most resembles the randomized double-blind crossover trial conducted by 
Davies et al., which provided a standardized placebo and a controlled diet to participants. 
The study included similar treatment duration, tea dosages, and population as the current 
trial. The work by Davies et al., however, differed from the current trial in that they 
provided the National Cholesterol Education Program Step I-type diet and, initially, a 
placebo without caffeine. Furthermore, the study added a post hoc treatment arm with a 
caffeinated placebo. Their results showed that 15 mildly hypercholesterolemic adults 
experienced declines in TC (3.8%; p=0.06, trend) and LDL-C (7.5%; p=0.01) concentrations 
after consumption of black tea compared to placebo without caffeine. The comparison of tea 
consumption to a caffeinated placebo during a post hoc treatment period resulted in 
differences of 6.5% TC (p=<0.001) and 11.1% LDL-C (p=0.002) across treatment groups, 
larger differences than found when comparing tea to the non-caffeinated placebo. These 
results contradict the results of multiple clinical trials published on this topic to date, 
including the current trial. The incorporation of a post hoc third treatment period with 12 of 
15 original trial participants, during which all participants consumed a caffeinated placebo 
drink, may have contributed to the large effects observed in this trial.36
Participants in the current study served as their own controls, which reduced error variance 
and the potential for observation bias. Participants were highly compliant with study 
procedures, and there was minimal loss-to-follow-up. We estimated that the respective 
lengths of the treatment and washout periods were appropriate to observe the effect of 
interest and eliminate carry over effects of treatment due to the short time required for re-
equilibration of the parent catechin and catechin metabolite concentrations after a high 
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intake of tea.42,46–48,50 Conversely, lipophilic metabolites of catechins may need a longer 
period of time for re-equilibration, but no carry over effect was seen as lipid concentrations 
returned to baseline during the washout period. The use of absolute cholesterol 
concentrations in the primary outcome analyses, versus measures of difference, was 
appropriate, as cholesterol concentration equilibration occurs within two weeks.42
Limitations of the present trial include an inability to test for dose response relationships 
between tea and lipid concentrations, and to evaluate the effects of tea consumption against 
different background diets. Also, while study staff carefully monitored participant 
compliance via multiple mechanisms, no biological analyses were conducted to validate 
self-reported compliance, a potential weakness shared with most other trials on this subject.
CONCLUSIONS
In summary, the intake of 5 cups of tea in combination with a low-flavonoid typical 
American diet did not significantly alter the lipid profile of borderline hypercholesterolemic 
participants. While tea may have very small beneficial effects on lipid profiles, this trial 
indicates that there is little therapeutic benefit to using black tea beverage to prevent 
hypercholesterolemia progression. Further research is needed to explore other tea-
consumption-related mechanisms of potential importance in cardiovascular disease etiology, 
e.g. improvement of endothelial function, inflammation reduction, platelet hyperactivity, 
and oxidative damage.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline characteristics by primary treatment assignment of participants in a study to examine the effect of 5 









% Female 46.7 40.7
Age (years) 51.7 (5.1) 53.2 (4.9)
BMI 31.4 (5.8) 30.0 (6.1)
Systolic Blood Pressure (mm
Hg)
130.1 (15.2) 129.2 (12.0)
Total Cholesterol (mg/dl) 207.2a (27.9) 206.7 (22.8)
HDL-C (mg/dl)* 38.6a (8.3) 43.3 (9.2)
LDL-C (mg/dl) 128.0b (20.0) 133.6c (25.9)
VLDL-C (mg/dl) 44.5a (34.9) 34.8 (35.7)
TG (mg/dl) 222.7a (174.4) 174.1 (178.5)
AST (U/L)d 22.6a (7.4) 24.9 (7.7)
Glucose (mg/dl)d 100.9a (15.1) 99.1 (8.0)
Creatinine (mg/dl)d 0.9a (0.2) 1.0 (0.1)




Serum TC, HDL-C, VLDL-C, TG, AST, glucose, and creatinine value not available for 1 participant
b
LDL-C value calculated using Friedewald equation. Cannot be estimated for 5 participants with >400 mg/dl TG (>4.5 mmol/L)
c
LDL-C calculated using Friedewald equation. Cannot be estimated for 2 participants with >400 mg/dl TG (>4.5 mmol/L)
d
Values from eligibility visit.
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